1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

  • December 2017
  • 32 pages
  • ID: 5257630
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

Summary
Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time (NIH, 2010). As the disease progresses, the symptoms worsen, eventually leading to kidney failure (NIH, 2010). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease, Improving Global Outcomes (KDIGO) classification system is considered the standard for GFR measurement and diagnosis of CKD.

CKD affects people of all ages, but the risk is higher in those ages 65 years and older. Globally, the estimated prevalence of CKD is around 7% in people over the age of 30 years (Zhang and Rothenbacher, 2008). In addition, CKD is more common in women thanmen, and is also more common in people of African and South Asian origin due to the high prevalence of diabetes in South Asians and hypertension in people of African origin.

In the 7MM, our epidemiologists forecast the diagnosed prevalent cases of CKD, Stages I-V, to increase from around 25.7 million cases in 2016 to over 28.3 million cases in 2026, at an Annual Growth Rate (AGR) of almost 1%. The UK will have the highest number of diagnosed cases of CKD throughout the forecast period.

The report "EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026", provides an overview of the risk factors, comorbidities, and the global and historical trends of CKD in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I-IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I-V, and the diagnosed prevalent cases of CKD by stage.

Scope
- The Chronic Kidney Disease EpiCast Report provides an overview of the risk factors and global trends of chronic kidney disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I-IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I-V, and the diagnosed prevalent cases of CKD by stage.
- The chronic kidney disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The Chronic Kidney Disease EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease treatment market.
- Quantify patient populations in the chronic kidney disease market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chronic kidney disease therapeutics in each of the markets covered.
- Understand magnitude of chronic kidney disease.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($3995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028

  • $ 3995
  • December 2019

Chronic Obstructive Pulmonary Disease: Epidemiology Forecast to 2028SummaryChronic Obstructive Pulmonary Disease (COPD) is a progressive disease characterized by coughing that produces large amounts of ...

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2019

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease (Chronic Renal Failure) - Pipeline ...

Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2019

Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2019

  • $ 2500
  • December 2019

Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2019Summaryclinical trial report, “Left Ventricular Dysfunction Global Clinical Trials Review, H2, 2019" provides an overview of Left Ventricula ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on